Phys.org reported that Eden Radioisotopes LLC, which was founded last year, has licensed a technology that will allow it to make molybdenum-99, a radioactive isotope “needed for diagnostic imaging in nuclear medicine.”
As quoted in the market news:
It hopes to build the first U.S. reactor for making the isotope and become a global supplier.
‘One of the pressing reasons for starting this company is the moly 99 shortages that are imminent in the next few years,’ said Chris Wagner, Eden’s chief operating officer and a 30-year veteran of the medical-imaging industry. ‘We really feel this is a critical time period to enter the market and supply replacement capacity for what is going offline.’